subject: ViiV Healthcare announces HIV/AIDS initiatives to improve access to medicines [print this page] ViiVHealthcare acknowledges the contribution of Shire Pharmaceuticals Group plc, which has a Master Licence agreement with ViiVHealthcare, for products containing lamivudine; and of Shionogi co-developer of the integrase inhibitor with ViiVHealthcare that have also agreed to waive its rights to royalty payments in order to improve access for these products.
ViiV Healthcare announces HIV/AIDS initiatives to improve access to medicines
